- Home
- CLDI vs IHT Comparison
CLDI vs IHT Comparison
Compare CLDI & IHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLDI | IHT |
|---|---|---|
| Founded | 2014 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 15.2M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CLDI | IHT |
|---|---|---|
| Price | $1.18 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 56.4K | 24.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $45,000.00 | ★ $7,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.33 |
| 52 Week Low | $0.09 | $0.95 |
| 52 Week High | $1.93 | $3.31 |
Technical Indicators
Market Signals| Indicator | CLDI | IHT |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 35.66 |
| Support Level | $1.12 | $1.23 |
| Resistance Level | $1.42 | $1.51 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 10.00 | 40.98 |
Price Performance
Historical ComparisonAbout CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.